Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B. 1.1. 7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort …
D Frampton, T Rampling, A Cross, H Bailey… - The Lancet infectious …, 2021 - thelancet.com
D Frampton, T Rampling, A Cross, H Bailey, J Heaney, M Byott, R Scott, R Sconza, J Price…
The Lancet infectious diseases, 2021•thelancet.comBackground Emergence of variants with specific mutations in key epitopes in the spike
protein of SARS-CoV-2 raises concerns pertinent to mass vaccination campaigns and use of
monoclonal antibodies. We aimed to describe the emergence of the B. 1.1. 7 variant of
concern (VOC), including virological characteristics and clinical severity in
contemporaneous patients with and without the variant. Methods In this cohort study,
samples positive for SARS-CoV-2 on PCR that were collected from Nov 9, 2020, for patients …
protein of SARS-CoV-2 raises concerns pertinent to mass vaccination campaigns and use of
monoclonal antibodies. We aimed to describe the emergence of the B. 1.1. 7 variant of
concern (VOC), including virological characteristics and clinical severity in
contemporaneous patients with and without the variant. Methods In this cohort study,
samples positive for SARS-CoV-2 on PCR that were collected from Nov 9, 2020, for patients …
Background
Emergence of variants with specific mutations in key epitopes in the spike protein of SARS-CoV-2 raises concerns pertinent to mass vaccination campaigns and use of monoclonal antibodies. We aimed to describe the emergence of the B.1.1.7 variant of concern (VOC), including virological characteristics and clinical severity in contemporaneous patients with and without the variant.
Methods
In this cohort study, samples positive for SARS-CoV-2 on PCR that were collected from Nov 9, 2020, for patients acutely admitted to one of two hospitals on or before Dec 20, 2020, in London, UK, were sequenced and analysed for the presence of VOC-defining mutations. We fitted Poisson regression models to investigate the association between B.1.1.7 infection and severe disease (defined as point 6 or higher on the WHO ordinal scale within 14 days of symptoms or positive test) and death within 28 days of a positive test and did supplementary genomic analyses in a cohort of chronically shedding patients and in a cohort of remdesivir-treated patients. Viral load was compared by proxy, using PCR cycle threshold values and sequencing read depths.
Findings
Of 496 patients with samples positive for SARS-CoV-2 on PCR and who met inclusion criteria, 341 had samples that could be sequenced. 198 (58%) of 341 had B.1.1.7 infection and 143 (42%) had non-B.1.1.7 infection. We found no evidence of an association between severe disease and death and lineage (B.1.1.7 vs non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 0·97 [95% CI 0·72–1·31]), or in analyses adjusted for hospital, sex, age, comorbidities, and ethnicity (adjusted PR 1·02 [0·76–1·38]). We detected no B.1.1.7 VOC-defining mutations in 123 chronically shedding immunocompromised patients or in 32 remdesivir-treated patients. Viral load by proxy was higher in B.1.1.7 samples than in non-B.1.1.7 samples, as measured by cycle threshold value (mean 28·8 [SD 4·7] vs 32·0 [4·8]; p=0·0085) and genomic read depth (1280 [1004] vs 831 [682]; p=0·0011).
Interpretation
Emerging evidence exists of increased transmissibility of B.1.1.7, and we found increased virus load by proxy for B.1.1.7 in our data. We did not identify an association of the variant with severe disease in this hospitalised cohort.
Funding
University College London Hospitals NHS Trust, University College London/University College London Hospitals NIHR Biomedical Research Centre, Engineering and Physical Sciences Research Council.
thelancet.com